Zobrazeno 1 - 10
of 38
pro vyhledávání: ''
Autor:
Bruce A. Littlefield, Elodie Modave, Amy Weaver, Bram Boeckx, Diether Lambrechts, Agnieszka Wozniak, Patrick Schöffski
Publikováno v:
Clinical Cancer Research. 27:3106-3115
Purpose:A randomized phase III study evaluated the efficacy of eribulin versus dacarbazine in patients with advanced liposarcoma and leiomyosarcoma. Improved overall survival (OS) led to approval of eribulin for liposarcoma, but not for leiomyosarcom
Autor:
Satoshi Yoda, Wafa Malik, Adam Langenbucher, Justin F. Gainor, Sai-Hong Ignatius Ou, Kylie Prutisto-Chang, Ramin Sakhtemani, Jennifer L Peterson, Aaron N. Hata, Alexander Drilon, Andrew Do, Jessica J. Lin, Adam J. Schoenfeld, Viola W. Zhu, Ted William Johnson, Jochen K. Lennerz, Lecia V. Sequist, Noura J. Choudhury, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Christina Falcon, Charlotte E. Lee, Alice T. Shaw, Michael S. Lawrence, Beow Y. Yeap, Jennifer S. Temel, Harper Hubbeling
Publikováno v:
Clin Cancer Res
Purpose: Current standard initial therapy for advanced, ROS proto-oncogene 1, receptor tyrosine kinase fusion (ROS1)-positive (ROS1+) non–small cell lung cancer (NSCLC) is crizotinib or entrectinib. Lorlatinib, a next-generation anaplastic lymphoma
Autor:
Richard Price, Christine Ju, Johanna C. Bendell, Herbert Hurwitz, Xiaoju Max Ma, John Lee, Nalin Tikoo, Christoph Mancao, Lijing Yao, Alex Lovejoy, Alan Nicholas, Stephanie J. Yaung, John F. Palma, Nicolas Sommer
Publikováno v:
Clinical Cancer Research. 26:4010-4017
Purpose:We assessed plasma circulating tumor DNA (ctDNA) level as a prognostic marker for progression-free survival (PFS) following first-line metastatic colorectal cancer (mCRC) therapy.Experimental Design:The Sequencing Triplet With Avastin and Mai
Reciprocal and Autonomous Glucocorticoid and Androgen Receptor Activation in Salivary Duct Carcinoma
Publikováno v:
Clin Cancer Res
Purpose: To determine the expression of glucocorticoid receptor (GR) and androgen receptor (AR) in salivary duct carcinoma (SDC) and to analyze the role of these proteins in the development and management of this disease entity. Experimental Design:
Autor:
Genta Nagae, Kazuhiko Koike, Hayato Nakagawa, Yutaka Midorikawa, Shogo Yamamoto, Kenji Tatsuno, Kyoji Moriya, Tadatoshi Takayama, Mitsuhiko Moriyama, Hiroyuki Aburatani
Publikováno v:
Clinical Cancer Research. 25:6217-6227
Purpose:Hepatitis B viral (HBV) DNA is frequently integrated into the genomes of hepatocellular carcinoma (HCC) in patients with chronic HBV infection (chronic HBV, hereafter), whereas the frequency of HBV integration in patients after the disappeara
Autor:
Tobias Herold, Luise Hartmann, Wolfgang Hiddemann, Philipp A. Greif, Daniela Schumacher, Bianka Ksienzyk, Claudia D. Baldus, Bernhard Wörmann, Evelyn Zellmeier, Stephan Wolf, Sebastian Vosberg, Friederike Pastore, Helmut Blum, Stephanie Schneider, Sophie M. Stief, Stefanos A. Bamopoulos, Wolfgang E. Berdel, Ines Hellmann, Stefan Krebs, Alexander Graf, Karsten Spiekermann, Klaus H. Metzeler, Stefan K. Bohlander, Vindi Jurinovic, Nikola P. Konstandin, Raphael Mattes, Dennis Görlich, Martin Neumann, Kathrin Bräundl, Paul Kerbs
Publikováno v:
Clinical Cancer Research. 24:1716-1726
Purpose: To study mechanisms of therapy resistance and disease progression, we analyzed the evolution of cytogenetically normal acute myeloid leukemia (CN-AML) based on somatic alterations. Experimental Design: We performed exome sequencing of matche
Publikováno v:
Clinical Cancer Research. 23:3884-3895
Purpose: Human papillomavirus 16 (HPV-16) is an important risk factor in head and neck cancer (HNC). Studies suggest that miRNAs play an important role in cancer; however, their role in HPV-mediated oncogenesis remains largely unknown. We investigate
Autor:
Stephen N. Thibodeau, Michelle R. Mahoney, Richard M. Goldberg, Harry H. Yoon, Daniel J. Sargent, Thomas C. Smyrk, Steven R. Alberts, Frank A. Sinicrope, Garth D. Nelson
Publikováno v:
Clinical Cancer Research. 21:5294-5304
Purpose: To determine the frequency and prognostic association of molecular markers by anatomic tumor site in patients with stage III colon carcinomas. Experimental Design: In a randomized trial of adjuvant FOLFOX ± cetuximab, BRAFV600E and KRAS (ex
Autor:
Chang-Qi Zhu, Melania Pintilie, Desmond She, Frances A. Shepherd, Shingo Sakashita, David W. Cescon, Ming-Sound Tsao
Publikováno v:
Clinical Cancer Research. 21:2499-2505
Purpose: Genomic profiling of lung squamous cell carcinomas (SCC) has identified NRF2 pathway alterations, which activate oxidative response pathways, in one third of tumors. Preclinical data suggest these tumors may be resistant to platinum-based ch
Autor:
Anne de la Rochefordière, Ivan Bièche, Virginie Fourchotte, Florence Joly, Emmanuel Sevin, Béatrice Weber, Mathieu Minsat, Benard Asselain, Anne Floquet, Maud Kamal, Suzy Scholl, Maud Aumont, Quentin Leroy, Laurence Thomas, Marius Pop, Alhassane Diallo, Sophie Maillard, Hervé Curé, Michel Fabbro, Peter Petrow, Philippe Beuzeboc, Thierry Petit, K. Peignaux, Laurence Gladieff, Corine Plancher, Laurence Gonzague, Virginie Bernard, Claire Brunaud, Christine Kerr, Dominique Berton-Rigaud, AnaTereza Nadan, Sebastien Armanet, Audrey Margogne
Publikováno v:
Clinical Cancer Research. 21:2530-2537
Purpose: EGFR is frequently overexpressed in cervical cancer, suggesting EGFR blockade as a promising treatment approach. Cetuximab, an anti EGFR antibody, used conjointly with radiochemotherapy, was feasible in first-line treatment of cervix carcino